1 Ganem D,Prince AM.Hepatitis B virus infection- natural history and clinical consequences.N Engl J Med, 2004, 350:1118-1129.
2 Stibbe W,Gerlich WH. Variable protein composition of hepatitis B surface antigen from different donors. Virology, 1982, 123: 436-442.
3 盛欢,胡晓波,许洁.两种方法检测HBsAg定量结果的临床互认研究.检验医学,2013, 28: 828-834.
4 Sonneveld MJ, Rijckborst V, Boucher CA, et al. A comparison of two assays for quantification of Hepatitis B surface antigen in patients with chronic hepatitis B. J Clin Virol, 2011, 51: 175-178.
5 Su TH, Hsu CS, Chen CL, et al.Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther, 2010, 15: 1133-1139.
6 裴彦祯,韩涛,马晓艳,等.HBsAg及HBV DNA定量水平在慢性乙型肝炎、肝硬化和肝癌患者中的变化.中华肝脏病杂志,2011,19: 743-746.
7 Chan HL,Wong VW,Wong GL,et al.A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B.Hepatology, 2010, 52: 1232-1241.
8 Thompson AJ,Nguyen T,Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intra-hepatic hepatitis B virus markers.Hepatology, 2010, 51:1933-1944.
9 Jaroszewicz J,Calle Serrano B,Wursthorn K,et al. Hepatitis B surface antigen(HBsAg)levels in the natural history of hepatitis B virus (HBV)-infection:a European perspective.J Hepatol, 2010, 52: 514-522.
10 Nguyen T,Thompson AJ,Bowden S,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.J Hepatol, 2010, 52: 508-513.
11 Kim YJ,Cho HC,Choi MS,et al.The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int, 2011, 31: 817-823.
12 Ozdil B, Cosar AM, Akkiz H, et al.Negative correlation between viral load and HBsAg levels in chronic HBV-infected patients. Arch Virol, 2009, 154:1451-1455.
13 徐美,吴金明,傅蓓蓓,等.乙型肝炎病毒慢性感染自然病程中HBsAg变化规律.医学研究杂志,2014,43: 40-45.
14 Chan HL,Wong VW, Tse AM ,et al.Serum hepatitis B surface antigen quantitation can reflect Hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol, 2007, 5: 1462-1468.
15 Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induces strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 2006, 44: 675-684.
16 Chaudhuri V1, Tayal R, Nayak B, et al. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter.Gastroenterology, 2004, 127: 1356-1371.
17 刘爱平,叶军,耿爱文.慢性乙型肝炎患者肝细胞内HBsAg、HBcAg的表达与肝组织病理、血清HBV DNA定量关系.实用临床医药杂志,2013,17: 16-19.
18 Marusawa HI, Uemoto S,Hijikata M,et al.Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology, 2000, 31: 488-495.
19 韩聚强,胡大荣,熊锦华等.C基因截短的HBV复制与包装.中华实验和临床病毒学杂志,2004,18: 39-42.
20 Günther S,Piwon N,Jung A, et al.Enhanced replication contributes to enrichment of hepatitis B virus with a deletion in the core gene.Virology, 2000, 273: 286-299.
21 Kremsdorf D,Garreau F,Duclos H, et al.Complete nucleotide sequence and viral envelope protein expression of a hepatitis B virus DNA derived from a hepatitis B surface antigen-seronegative patient.J Hepatol, 1993, 18: 244-250.
22 Chan HL,Wong GL,Tse CH,et al.Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis, 2011, 204: 408-414.
23 Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol, 2013, 58: 853-860.
24 冯振华,张姝,刘景丽,等.慢性HBV携带孕妇产后自发HBeAg和HBsAg血清清除或转换的病毒学因素分析. 实用肝脏病杂志,2014,17: 376-379.
25 Brunetto MR,Oliveri F,Colombatto P,et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carrier.Gastroenterology, 2010, 139: 483-490.
26 Sonneveld MJ,Zoutendijk R,Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B.J Viral Hepat, 2011, 18: 449-457.
27 Tan Z,Li M,Kuang X, et al. Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection. J Clin Virol, 2014, 59:228-234.
28 Chan HL,Wong VW,Chim AM,et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther, 2010, 32: 1323-1331.
29 Chan HL,Thompson A,Martinot-Peignoux M, et al.Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report. J Hepatol, 2011, 55: 1121-1131.
30 Sonneveld MJ,Rijckborst V,Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology, 2010, 52: 1251-1257.
31 Moucari R, Mackiewicz V, Lada O, et al.Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology, 2009, 49: 1151-1157.
32 肖作汉, 孟冈, 王立志. HBsAg定量对HBeAg阴性患者PEG-IFN治疗应答的预测. 肝脏,2014, 19: 949-951.
33 Rijckborst V,Hansen BE,Cakaloglu Y,et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic heaptitis Busing HBsAg and HBV DNA levels. Hepatology, 2010, 52: 454-461.
34 陈新月. 提高HBeAg阳性慢性乙型肝炎患者持久免疫控制治疗策略. 中华肝脏病杂志, 2013, 21: 484-487.
35 顾生旺, 刘欢, 赵兵, 等. 552例乙型肝炎患者HBsAg与HBeAg定量反弹情况分析. 肝脏, 2015, 20: 495-497.
36 Wursthorn K,Jung M,Riva A,et al.Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology, 2010, 52: 1611-1620.
37 Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology, 2013, 58: 923-931.
38 Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol, 2010, 48: 22-26.
39 秦来英, 刘葵花, 张照华, 等. 拉米夫定治疗期间患者血清乙型肝炎表面抗原定量的变化. 中华肝脏病杂志, 2005, 13: 602-602.
40 Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther, 2010, 15: 471-475. |
